ZA200808596B - Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors - Google Patents

Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors

Info

Publication number
ZA200808596B
ZA200808596B ZA200808596A ZA200808596A ZA200808596B ZA 200808596 B ZA200808596 B ZA 200808596B ZA 200808596 A ZA200808596 A ZA 200808596A ZA 200808596 A ZA200808596 A ZA 200808596A ZA 200808596 B ZA200808596 B ZA 200808596B
Authority
ZA
South Africa
Prior art keywords
receptors
preparation
inhibit vanilloid
ureas
indazolyl
Prior art date
Application number
ZA200808596A
Other languages
English (en)
Inventor
Kirill A Lukin
Hsu Margaret Chi-Ping
Dilinie P Fernando
Brian J Kotecki
Marvin R Leanna
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ZA200808596B publication Critical patent/ZA200808596B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ZA200808596A 2006-04-14 2008-10-08 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors ZA200808596B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79209906P 2006-04-14 2006-04-14

Publications (1)

Publication Number Publication Date
ZA200808596B true ZA200808596B (en) 2010-03-31

Family

ID=38610399

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808596A ZA200808596B (en) 2006-04-14 2008-10-08 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors

Country Status (21)

Country Link
US (2) US7847104B2 (xx)
EP (1) EP2012779B1 (xx)
JP (1) JP2009533474A (xx)
KR (2) KR101118932B1 (xx)
CN (4) CN102140081A (xx)
AU (1) AU2007238019B2 (xx)
BR (1) BRPI0709963A2 (xx)
CA (1) CA2647261A1 (xx)
CR (1) CR10357A (xx)
EC (1) ECSP088878A (xx)
ES (1) ES2385404T3 (xx)
HK (1) HK1123725A1 (xx)
MX (1) MX2008013205A (xx)
MY (1) MY145334A (xx)
NO (1) NO20084698L (xx)
NZ (1) NZ571705A (xx)
RU (1) RU2446161C2 (xx)
TW (1) TW200815362A (xx)
UA (1) UA94100C2 (xx)
WO (1) WO2007121339A2 (xx)
ZA (1) ZA200808596B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055730A1 (en) * 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
WO2009117626A2 (en) * 2008-03-20 2009-09-24 Abbott Laboratories Methods for making central nervous system agents that are trpv1 antagonists
CN102070420B (zh) * 2011-01-04 2013-12-18 常州大学 一种2-溴-6-氟苯甲醛的制备方法
WO2014158640A1 (en) * 2013-03-13 2014-10-02 Dow Agrosciences Llc Improved process for the preparation of certain triaryl rhamnose carbamates
MX2019000512A (es) 2016-07-12 2019-05-02 Bayer Cropscience Ag Compuestos biciclicos como plaguicidas.
CN106977535A (zh) * 2017-04-28 2017-07-25 大连联化化学有限公司 一种合成2‑氰基3‑氟苯硼酸工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (xx) * 1963-08-09
DE2458965C3 (de) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
US5905080A (en) * 1993-08-20 1999-05-18 Smithkline Beecham, P.L.C. Amide and urea derivatives as 5HT1D receptor antagonists
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
JP2005533014A (ja) * 2002-04-26 2005-11-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換ピラジン誘導体
DK1638941T3 (da) * 2003-05-22 2010-10-11 Abbott Lab Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
AU2004275694B2 (en) * 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20070021450A1 (en) * 2004-07-16 2007-01-25 Benjamin Sklarz Indanylamino uracils and their use as antioxidants and neuroprotectants
WO2006020070A2 (en) * 2004-07-16 2006-02-23 Teva Pharmaceutical Industries, Ltd. Indanylamino uracils and their use as antioxidants and neuroprotectants
US8071609B2 (en) * 2005-08-11 2011-12-06 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
WO2007056075A2 (en) * 2005-11-02 2007-05-18 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
CA2629962A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles and aza-substituted indoles

Also Published As

Publication number Publication date
CN101466374B (zh) 2012-03-21
RU2008144961A (ru) 2010-05-20
CN101466374A (zh) 2009-06-24
US8519186B2 (en) 2013-08-27
RU2446161C2 (ru) 2012-03-27
CN102321025A (zh) 2012-01-18
AU2007238019A1 (en) 2007-10-25
ECSP088878A (es) 2008-12-30
CA2647261A1 (en) 2007-10-25
WO2007121339A2 (en) 2007-10-25
KR101118932B1 (ko) 2012-02-27
WO2007121339A3 (en) 2008-10-02
KR20110017464A (ko) 2011-02-21
UA94100C2 (ru) 2011-04-11
US20110040102A1 (en) 2011-02-17
EP2012779B1 (en) 2012-05-16
HK1123725A1 (en) 2009-06-26
MX2008013205A (es) 2008-10-22
US7847104B2 (en) 2010-12-07
AU2007238019B2 (en) 2013-03-14
JP2009533474A (ja) 2009-09-17
CR10357A (es) 2008-12-11
MY145334A (en) 2012-01-31
EP2012779A4 (en) 2010-11-24
CN102775350A (zh) 2012-11-14
EP2012779A2 (en) 2009-01-14
US20070244178A1 (en) 2007-10-18
KR20090003335A (ko) 2009-01-09
ES2385404T3 (es) 2012-07-24
TW200815362A (en) 2008-04-01
BRPI0709963A2 (pt) 2011-08-02
NZ571705A (en) 2012-03-30
CN102140081A (zh) 2011-08-03
NO20084698L (no) 2008-11-07

Similar Documents

Publication Publication Date Title
ZA200808691B (en) Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
IL183321A0 (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
HK1157757A1 (zh) 製備環巴胺類似物化合物的方法
HK1123725A1 (en) Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors
DK3872059T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
PL1806330T3 (pl) Sposób wytwarzania 1-butenu z technicznych mieszanin węglowodorów C<sub>4</sub>
ZA200707614B (en) Process for the polymerizatio of olefins
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
PL1743882T3 (pl) Sposób do produkcji izocyjanianów
IL187208A0 (en) Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
PL2222678T3 (pl) Sposoby wytwarzania związków morfinanowych (+)-'nal'
ZA200805162B (en) Novel benzimidazole derivatives as vanilloid receptor 1 (VRL) inhibitors
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
EG25547A (en) Process for the preparation of amines
HK1144682A1 (en) Process for the preparation of alkyl 3,3-dialkoxypropionates 33-
WO2009076408A3 (en) 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
GB2441840B (en) Process for the synthesis of arylfluorenes and analogues thereof
IL206570A (en) 4,3-Dihydro Compound-1 h- Isoquinoline is converted into 3 positions, process for preparation and use
EP2084168A4 (en) METHOD FOR PRODUCING HIGH-PURITY DIALKYL DITHIOPHOSPHIN COMPOUNDS
ZA200704722B (en) Process for the preparation of lower olefins from heavy wax
HK1128287A1 (en) Process for the preparation of tryptase inhibitors
ZA200804778B (en) New process for the preparation of esomeprazole non-salt form
IL177353A0 (en) Process for the preparation of aq4n
ZA200607540B (en) Process for the preparation of substituted triazole compounds